Gelteq Announces New Product Development Agreement with Melbourne Health for Novel Bowel Polyp Growth Reduction Compound [Yahoo! Finance]
Gelteq Limited - Ordinary Shares (GELS)
Company Research
Source: Yahoo! Finance
and science-based company specialising in gel-based oral delivery solutions, today announced it has entered into a Product Development and Profit Share Agreement (the “Agreement”), with Melbourne Health (“Melbourne Health”), operator of The Royal Melbourne Hospital and one of Australia's top public health services with extensive research capabilities. Under the Agreement, Gelteq and Melbourne Health will develop new products incorporating high-amylose maize starch butyrylated, or HAMSB, a unique compound with the potential to reduce bowel polyp growth which could lower the risk of bowel cancer. HAMSB, a form of acylated starch, has been the focus of significant research conducted by the Melbourne Health and the Commonwealth Scientific and Industrial Research Organisation (“CSIRO”). A recent study has demonstrated HAMSB's significant effects on polyp initiation pointing towards an alternative and innovative approach in colorectal health management. The results of this Australian st
Show less
Read more
Impact Snapshot
Event Time:
GELS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GELS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GELS alerts
High impacting Gelteq Limited - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
GELS
News
- Gelteq Preclinical Study Demonstrates Enhanced Oral Delivery of Oil-Soluble and Poorly Soluble Drugs Using Its Gel-Based Platform [Yahoo! Finance]Yahoo! Finance
- Gelteq Preclinical Study Demonstrates Enhanced Oral Delivery of Oil-Soluble and Poorly Soluble Drugs Using Its Gel-Based PlatformGlobeNewswire
- Gelteq to Present at Investor Summit Virtual on December 9, 2025 [Yahoo! Finance]Yahoo! Finance
- Gelteq to Present at Investor Summit Virtual on December 9, 2025GlobeNewswire
- Gelteq Announces Positive Preclinical Results Demonstrating Enhanced Bioavailability Using Its Proprietary Gel-Based Drug Delivery PlatformGlobeNewswire
GELS
Sec Filings
- 11/17/25 - Form 20-F
- 11/3/25 - Form NT
- GELS's page on the SEC website